<DOC>
	<DOCNO>NCT02464969</DOCNO>
	<brief_summary>To assess safety extrapolate efficacy apixaban pediatric subject require anticoagulation treatment VTE .</brief_summary>
	<brief_title>Apixaban Acute Treatment Venous Thromboembolism Children</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>1 . 12 &lt; 18 year age time consent . 2 . Presence index VTE confirm image . 3 . Intention manage index VTE anticoagulation treatment least 12 week . 1 . Anticoagulant treatment index VTE great 7 day prior randomization . 2 . Thrombectomy , thrombolytic therapy , insertion caval filter treat index VTE . 3 . A mechanical heart valve . 4 . Active bleeding high risk bleeding time randomization . 5 . Intracranial bleed , include intraventricular hemorrhage , within 3 month prior randomization . 6 . Abnormal baseline liver function randomization . 7 . Inadequate renal function time randomization . 8 . Platelet count &lt; 50Ã—109 per L randomization . 9 . Uncontrolled severe hypertension time randomization . 10 . Use prohibit concomitant medication time randomization . 11 . Female subject either pregnant breastfeeding child .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>VTE , thromboembolism , thrombosis , embolism , apixaban , Eliquis</keyword>
</DOC>